Short sellers are betting against Auris Medical Holding AG (NASDAQ:EARS). Looking at the sentiment indicator for the EARS stock we see that the short-interest ratio is at 1 while the average analyst recommendations at 2 suggests buying these shares. Between January 15 and January 31, the total number of shorted shares amounted to 825.57 thousand shares. That was 8.92% more than the total of 757.94 thousand shares in the space of prior two weeks, which means more traders or funds betting that the stock will go down. Average daily volume for Auris Medical Holding AG at the January 31st settlement jumped to 2,397,865, as compared to 1,481,314 at the January 15th report. That brought days to cover to a 0% decrease from the 1 days to cover recorded at the prior short interest data release.
The stock is currently hovering around the first support level of $0.36. Below this, the next support is placed in the zone of $0.32. Till the time, the EARS stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 44.28 on daily chart, which may remain a cause for concern. If the price breaks below $0.32 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.45 mark may result into a pull-back move towards $0.5 level.
On 13th of February, Auris Medical Holding AG (NASDAQ:EARS) shares ended higher after a volatile session. The shares accumulated 0.03 points or 9.17 percent at $0.39 with a heavy trade volume of 11.551 million shares. After opening the session at $0.43, the shares went as high as $0.47 and as low as $0.378, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $13.08 million and now has 33.18 million shares outstanding. Auris Medical Holding AG (EARS) stock has lost -8.52 percent of market value in 21 trading days.
EARS stock has a trailing 3-year beta of -0.56, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$1.92 a share in the trailing twelve months. The stock’s value has fallen -13.57 percent year to date (YTD) against a decline of -86.61 percent in 12 month’s time. The company’s shares still trade -88.74 percent away from its 1-year high of $3.50 and 71.35 percent up from 52-week low of $0.23. The average consensus rating on the company is 2, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of Auris Medical Holding AG (EARS) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry EARS operates in has an average P/E of 69.44. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 0 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 0 percent is the gross profit margin for Auris Medical Holding AG and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
Let’s take a look at some insider activity at Auris Medical Holding AG (NASDAQ:EARS) and see the pattern.